Systemic AA Amyloidosis Following Immune Checkpoint Inhibitor Therapy for Lung Carcinosarcoma: An Autopsy Case and Review of the Literature
Abstract
AA amyloidosis is a rare but serious complication of chronic inflammation. We report an autopsy case of a 68-year-old man without a documented history of inflammatory disease who developed lung carcinosarcoma and achieved a durable complete response after sequential immune checkpoint inhibitor (ICI) therapy. Despite tumor control, the patient developed a chronic intestinal pseudo-obstruction, persistent C-reactive protein elevation, progressive renal dysfunction, and later aspiration pneumonia. Autopsy revealed systemic AA amyloid deposition, predominantly in the intestines and kidneys, chronic thyroiditis, and tubulointerstitial nephritis. This case raises the possibility that prolonged inflammation during and after ICI therapy contributes to systemic AA amyloidosis.
Related
- Florbetaben PET for early and non-invasive diagnosis of light chain amyloidosis: a case report and brief review of the literature.
- A Common Small-Molecule Inhibitor Targeting Multiple Siglecs Associated with Immune Checkpoint Suppression of Cytotoxicity and Phagocytosis.
- Case Report: SMARCA4-deficient uterine sarcoma with exceptional response to immune checkpoint inhibitor therapy
- Outcomes following dialysis and transplantation in amyloidosis: ANZDATA analysis.
- Single-cell transcriptomics and whole-genome sequencing reveal the tumor landscape in breast carcinosarcoma
BibTeX
@article{onishi2026systemic,
title = {{Systemic AA Amyloidosis Following Immune Checkpoint Inhibitor Therapy for Lung Carcinosarcoma: An Autopsy Case and Review of the Literature}},
author = {Shinobu Onishi and Sari Iwasaki and Shimpei Nakagawa and Takuya Otsuka and Yuko Katayama and Satoshi Aoyama and Tetsuaki Shoji and Satoshi Tanaka and Jun Sakakibara-Konishi and Yoshihiro Matsuno and Shinya Tanaka and Koji Taniguchi},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.7265-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7265-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Systemic AA Amyloidosis Following Immune Checkpoint Inhibitor Therapy for Lung Carcinosarcoma: An Autopsy Case and Review of the Literature
AU - Shinobu Onishi
AU - Sari Iwasaki
AU - Shimpei Nakagawa
AU - Takuya Otsuka
AU - Yuko Katayama
AU - Satoshi Aoyama
AU - Tetsuaki Shoji
AU - Satoshi Tanaka
AU - Jun Sakakibara-Konishi
AU - Yoshihiro Matsuno
AU - Shinya Tanaka
AU - Koji Taniguchi
PY - 2026
DA - 2026/08/25
JO - Internal Medicine
DO - 10.2169/internalmedicine.7265-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7265-26/_article
AB - AA amyloidosis is a rare but serious complication of chronic inflammation. We report an autopsy case of a 68-year-old man without a documented history of inflammatory disease who developed lung carcinosarcoma and achieved a durable complete response after sequential immune checkpoint inhibitor (ICI) therapy. Despite tumor control, the patient developed a chronic intestinal pseudo-obstruction, persistent C-reactive protein elevation, progressive renal dysfunction, and later aspiration pneumonia. Autopsy revealed systemic AA amyloid deposition, predominantly in the intestines and kidneys, chronic thyroiditis, and tubulointerstitial nephritis. This case raises the possibility that prolonged inflammation during and after ICI therapy contributes to systemic AA amyloidosis.
SN - 1349-7235
SN - 0918-2918
ER -